A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 356
- Registration Number
- NCT03192176
- Locations
- ๐บ๐ธ
Research Site 052, Sacramento, California, United States
๐บ๐ธResearch Site 058, Sacramento, California, United States
๐บ๐ธResearch Site, Spokane, Washington, United States
A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT03092726
- Locations
- ๐บ๐ธ
Chicago Research Center, Inc, Chicago, Illinois, United States
๐บ๐ธLehigh Center for Clinical Research, Allentown, Pennsylvania, United States
๐บ๐ธPAB Clinical Research, Brandon, Florida, United States
A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
- Conditions
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03082300
- Locations
- ๐บ๐ธ
Beverly Hills Cancer Center, Beverly Hills, California, United States
๐บ๐ธRenovatio Clinical, The Woodlands, Texas, United States
๐บ๐ธUS Oncology - Virginia Cancer Specialists, P.C. (VCS), Fairfax, Virginia, United States
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT03070093
- Locations
- ๐บ๐ธ
University of Maryland Medical Center, Baltimore, Maryland, United States
๐บ๐ธThe Sidney Kimmel Comprehensive Cancer Center -Johns Hopkins University, Baltimore, Maryland, United States
๐บ๐ธUPCI, Pittsburgh, Pennsylvania, United States
Registry of Patients Treated With Systemic Mold-Active Triazoles
- Conditions
- Interventions
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 2015
- Registration Number
- NCT03066011
- Locations
- ๐บ๐ธ
Emory University, Atlanta, Georgia, United States
๐บ๐ธUniversity of Arizona, Tucson, Arizona, United States
๐บ๐ธStanford Health Care, Palo Alto, California, United States
A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT03065959
- Locations
- ๐บ๐ธ
Tufts Medical Center, Boston, Massachusetts, United States
๐บ๐ธWashington University School of Medicine, Saint Louis, Missouri, United States
๐บ๐ธOhio University Heritage College, Athens, Ohio, United States
A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 186
- Registration Number
- NCT03056690
- Locations
- ๐บ๐ธ
Site US10003 - Artemis Inst For Clin Research, San Diego, California, United States
๐บ๐ธSite US10056 - Atlanta Ctr for Med Research, Atlanta, Georgia, United States
๐บ๐ธSite US10038 - Heartland Research Associates, Wichita, Kansas, United States
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
- Conditions
- Interventions
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 1027
- Registration Number
- NCT03047083
- Locations
- ๐บ๐ธ
Sermo, Charlotte, North Carolina, United States
A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study
- Conditions
- Interventions
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT03042013
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 356
- Registration Number
- NCT02997202
- Locations
- ๐ฎ๐น
Site IT39009, Genova, Italy
๐ฉ๐ชSite DE49007, Mainz, Germany
๐ฎ๐นSite IT39004, Udine, Italy